For some lung cancer patients, Keytruda provides lasting benefit

Nearly one in five lung cancer patients treated with Merck & Co.'s immunotherapy Keytruda in an early study of the drug were alive five years later, a marked improvement over the average five-year survival rate of just 5% in the years before immuno-oncology's emergence.